English
Structure via PubChem · Public domain (PubChem)
tiamenidine
Sign in to saveTiamenidine (BAN, USAN, INN, also known as thiamenidine, Hoe 440) is an imidazoline compound that shares many of the pharmacological properties of clonidine. It is a centrally-acting α2 adrenergic receptor agonist (IC50 = 9.1 nM). It also acts as an α1-adrenergic receptor agonist to a far lesser extent (IC50 = 4.85 μM). In hypertensive volunteers, like clonidine, it significantly increased sinus node recovery time and lowered cardiac output. It was marketed (as tiamenidine hydrochloride) by Sanofi-Aventis under the brand name Sundralen for the management of essential hypertension.
In the Vinony graph
Within Vinony's link graph, tiamenidine is referenced by 604 other articles, and connects out to propranolol, atenolol and adrenergic receptor.
It sits within the topics Abandoned drugs, Alpha1-adrenergic agonists and Alpha2-adrenergic agonists.
Its subject is documented across 4 Wikipedia language editions.
Chemical data
- Formula
- C8H10ClN3S
- Molecular weight
- 215.7 g/mol
- IUPAC name
- N-(2-chloro-4-methylthiophen-3-yl)-4,5-dihydro-1H-imidazol-2-amine
- SMILES
- CC1=CSC(=C1NC2=NCCN2)Cl
- InChIKey
- CVWILQHZFWRYPB-UHFFFAOYSA-N
- XLogP
- 1.6
- Polar surface area
- 64.7 Ų
- H-bond donors
- 2
- H-bond acceptors
- 2
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 2
- Molecule type
- Small molecule
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 215.028
Show 3 more facts
- chemical formula
- C₈H₁₀ClN₃S
- canonical SMILES
- CC1=CSC(=C1NC2=NCCN2)Cl
- Commons category
- Tiamenidine
Sources (2)
via Wikidata · CC0
~1 min read
Encyclopedic overview
3 sectionsContents
- Synthesis
- See also
- References
Tiamenidine (BAN, USAN, INN, also known as thiamenidine, Hoe 440) is an imidazoline compound that shares many of the pharmacological properties of clonidine. It is a centrally-acting α2 adrenergic receptor agonist (IC50 = 9.1 nM). It also acts as an α1-adrenergic receptor agonist to a far lesser extent (IC50 = 4.85 μM). In hypertensive volunteers, like clonidine, it significantly increased sinus node recovery time and lowered cardiac output. It was marketed (as tiamenidine hydrochloride) by Sanofi-Aventis under the brand name Sundralen for the management of essential hypertension.
==Synthesis== [[File:Tiamenidine-synthesis.svg|500px|center|thumb|ChemDrug Synthesis: Patent:]]
Excerpted from Wikipedia’s “tiamenidine” article, available under the CC BY-SA 4.0 licence.